5 Recommendations for research

Intervention development and promotion

5.1 How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?

5.2 How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?

5.3 What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

5.4 What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

5.5 How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

5.6 What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?

5.7 What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

5.8 Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

Epidemiology

5.9 How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

5.10 How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

5.11 How cost effective are cohort testing programmes:

  • as a stand-alone programme, or

  • as an extension of the NHS Health Check programme?

    More detail on the gaps in the evidence identified during development of this guidance is provided in appendix D.